Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...

Celldex Therapeutics , Inc. (NASDAQ:CLDX), with a market capitalization of $1.72 billion, is a biopharmaceutical company focused on developing innovative therapies for challenging diseases, with its ...

Among significant research news last week, US biotech Allakos reported that it was dropping development of its urticaria ...

SAN CARLOS, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (Company) (Nasdaq: ALLK), today announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria ...

Allakos (NASDAQ:ALLK) has dropped ~75% in premarket trading Monday after posting disappointing phase 1 results on AK006 for chronic spontaneous urticaria and deciding to end development. Due to ...

Allakos, Bay Area biotech firm based in San Carlos, is laying off 75% of its staff and eyeing a shutdown after its clinical ...

A year after reducing half of its workforce, Allakos will downsize to just 15 employees as it halts the development of AK006.

A Bay Area biotech firm is laying off 75% of its staff following a flopped clinical trial. Allakos, based in San Carlos, ...

California, USA-based biotech Allakos saw its shares plummet 78.8% to $0.26 yesterday, after it announced disappointing ...

Constantly scratching and picking at an itchy rash really does make it worse. But why? According to newly released research ...

New research published in the journal Science uncovers how scratching aggravates inflammation and swelling in a mouse model ...

Scratching an itchy rash really does make it worse. Now we know why, thanks to new research that uncovers how scratching aggravates inflammation and swelling in a mouse model of a type of eczema ...